A Forbes opinion piece published September 21, 2026 argues that the FDA should restrict mass-market compounded versions of semaglutide and tirzepatide now that the GLP-1 drug shortage has been officially declared over. The article references a recent Fifth Circuit ruling that affirmed the FDA’s authority to remove GLP-1 drugs from the shortage list — a decision that effectively narrows the legal basis for compounders to mass-produce copycat versions.
The piece reflects a growing media and policy push for tighter enforcement as the compounding landscape shifts. No new FDA rule or enforcement action was announced in connection with the article.
What happened
Forbes published an opinion article on September 21, 2026 calling for an end to mass-market compounding of GLP-1 drugs. The author argues that with the shortage officially over, the legal basis for compounding pharmacies to produce copies of semaglutide and tirzepatide no longer applies.
The article cites a recent Fifth Circuit court ruling that upheld the FDA’s authority to remove GLP-1 drugs from the agency’s shortage list. Under existing compounding rules, removal from the shortage list is generally understood to restrict compounders’ ability to legally mass-produce that drug, though enforcement specifics remain to be seen.
The Forbes piece is an opinion and analysis article, not a regulatory action. No FDA rule, guidance, or enforcement decision was issued in connection with the publication.
Why it matters
The opinion piece signals a shift in the public debate around GLP-1 compounding. The central question is no longer whether compounding should end, but how quickly enforcement will tighten.
Several groups are directly affected by the evolving landscape:
- Compounding pharmacies and 503A facilities face increasing pressure as the legal basis for mass-producing GLP-1 copies narrows.
- Telehealth companies that sell compounded GLP-1 products may need to adjust their business models.
- GLP-1 patients using compounded versions could see changes in access.
- Brand-name drug manufacturers could benefit if compounded alternatives face reduced availability, though this outcome is not confirmed.
The combination of the Fifth Circuit ruling and media advocacy increases pressure on the FDA to accelerate restrictions on compounded GLP-1 products.
What to watch next
- Whether the FDA issues new enforcement guidance or timelines for winding down compounded GLP-1 production.
- How compounding pharmacies and telehealth companies respond to tightening restrictions.
- Whether additional legal challenges emerge over the scope of FDA authority on compounding.
- How patients currently using compounded GLP-1 drugs are affected as access shifts.
Sources
Forbes — “The GLP-1 Shortage Is Over: Mass-Market Compounding Should Be Too”
Industry information only. Not medical or legal advice.
